Camson Biotechnologies reports standalone Revenue of Rs. 1,226 Lakhs; EBITDA margin of 24%

Transcription

1

2 Camson Biotechnologies reports standalone Revenue of Rs. 1,226 Lakhs; EBITDA margin of 24% Standalone Performance Highlights Net Sales of Rs. 1,226 Lakhs EBITDA of Rs. 289 Lakhs; Margins at 24% Bangalore, India, November 14, 2015 Camson Biotechnologies Limited ( Camson Biotech or the Company ), India's first integrated IPR driven agricultural biotechnology company, announces its standalone Q2 and Half Year results for FY2016. Update on the Demerger of the Seeds business: Camson Biotech submitted an application under clause 24(f) of the listing agreement to the Bombay Stock Exchange which was duly approved by the same vide its letter dated 30 th January, Subsequently, the Scheme of Arrangement was approved by the Honourable High Court of Karnataka vide its order dated July 31 st, The Appointed Date of the Scheme of Arrangement is April 1 st, 2014 and the Scheme has become effective from September 1 st, Post filing of the Court order with the office of the Registrars of Companies, Camson Biotech has set the record date for the demerger as September 21 st, This is defined for the purpose of entitlement of shares of Camson Seeds Limited ( Camson Seeds ), which is to be listed separately in due course. Camson Biotech s shareholders will receive one equity share in Camson Seeds for every equity share owned in Camson Biotech. Consequently, the Company now operates in a single segment, i.e. Agri-Biotech. Q2 FY2016 results have been presented for the Agri-Biotech business and the results relating to previous quarter/period/year are not comparable. Q2 FY2016 Performance: Standalone revenue during Q2 FY2016 was Rs. 1,226 lakh at a Gross Margin of 77%. EBITDA during the quarter was Rs. 289 lakhs with a 24% margin. This quarter performance was undermined by the erratic and below normal monsoon which dampened the sentiment of the farmer community. Recent Corporate Developments: Camson Biotech introduced Calphomil in ginger crop segment in Kerala and Karnataka. Caltem, Calrrhiza and Calbahar products have been introduced for the Banana crop in UP. These represent significant wins given the large markets and crop segments. The Company signed a MoU with Zuari Agri Sciences. Under the MoU, Zuari will market Zero Residue biocides products manufactured by Camson Biotech. The arrangement 1 P a g e

3 brings out the best of both companies. While, Camson Biotech will leverage its technological and R&D firepower, Zuari will use its wide distribution network to market these products and spread the message of Zero Residue Cultivation across all sections of the farming community. Camson Biotech filed patents for its discovery of Natural Fertilizer, a product which is derived from microbial extracts. This is a breakthrough step wherein Natural Fertilizer has the capacity to replace synthetic fertilizer throughout the world. Being a clean technology it also addresses the concerns about the toxicity, safety and the environment issues facing the world. Commenting the business and performance, Mr. Santosh Nair, CEO of Camson Biotechnologies Limited said: Q2 FY2016 has been a very challenging period for the Indian agriculture industry due the erratic and below normal monsoon resulting in a drought like situation, particularly in southern India. While the season started well with reasonable rainfall in July-Aug but later during the season dried up. Due to the deficient monsoon, crop acreage and yields have been impacted putting a lot of pressure on the industry. This also had an impact on our top line. However, due to the management s ongoing focus on product mix rationalisation and cost optimisation initiatives, we managed to sustain the margin profile. On the operational front, we introduced our products in the key large markets and crop segments. This is a testament to the quality of our products and the strength of our marketing network. Our recent MoU with Zuari opens up an avenue to cover the broader market with our products through an institutional channel. We believe that such efforts and partnering together would not only add momentum but also go a long way in propagating the zero residue farming concept in the country. Overall, we are confident of our R&D prowess and product portfolio. Furthermore, after the demerger of Seeds business, we now have a much focused approach for our Biocides business and look forward to an exciting growth for the Company. 2 P a g e

4 About Camson: Camson Bio Technologies Limited ( Camson or the Company ) is India's first integrated IPR driven agricultural biotechnology company. Founded in 1993, Camson is headquartered in Bangalore, with primary focus on biotech R&D. The Company is a pioneer in zero residue farming products, which uses secondary metabolites (biological origin) of microbes to kill / inhibit pathogens, with no use of chemicals. It has been recognized by Deloitte as one the fastest growing technology companies in 2015 and conferred the Technology Fast 500 award and awarded the Leaders of Tomorrow Award by ET Now & Indiamart Contact Details: Camson Bio Technologies Limited (CIN: L85110KA1993PLC014944) C-7, 7th Floor, Corporate Block, Golden Enclave, Old Airport Road, Bangalore Santosh R Nair Camson Bio Technologies Saket Somani Churchgate Partners info@camsonbiotechnologies.com Camson@churchgatepartnersindia.com Safe Harbor: This release contains statements that contain forward looking statements including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Camson Biotech s future business developments and economic performance. While these forward looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macroeconomic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance. Camson Biotech undertakes no obligation to publicly revise any forward looking statements to reflect future / likely events or circumstances. 3 P a g e

5

6

7

8

9

10